Novartis AG (NVS)
| Market Cap | 262.89B +22.4% |
| Revenue (ttm) | 56.58B +6.3% |
| Net Income | 13.53B +5.2% |
| EPS | 6.98 +9.5% |
| Shares Out | 1.91B |
| PE Ratio | 19.42 |
| Forward PE | 15.35 |
| Dividend | $3.08 (2.15%) |
| Ex-Dividend Date | Mar 11, 2026 |
| Volume | 1,537,782 |
| Open | 142.47 |
| Previous Close | 143.48 |
| Day's Range | 142.26 - 144.26 |
| 52-Week Range | 112.34 - 170.46 |
| Beta | 0.49 |
| Analysts | Hold |
| Price Target | 153.87 (+7.11%) |
| Earnings Date | Jul 16, 2026 |
About NVS
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for NVS stock is "Hold." The 12-month stock price target is $153.87, which is an increase of 7.11% from the latest price.
News
Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients
Basel, June 3, 2026 – Novartis presented today new Cosentyx® (secukinumab) data in polymyalgia rheumatica (PMR) demonstrating a statistically significant, clinically meaningful difference in sustained...
Novartis announces 144-week data from ASC4FIRST trial of Scemblix
Novartis (NVS) announced positive 144-week data from the ASC4FIRST trial of Scemblix presented at the 2026 American Society of Clinical Oncology, ASCO, Annual Meeting. These results provide longer-ter...
Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases
Basel, June 1, 2026 – Novartis will present new data from 31 abstracts across its industry-leading immunology portfolio at the European Alliance of Associations for Rheumatology (EULAR) Congress on Ju...
Novartis announces results on rPFS improvements across subgroups with Pluvicto
Novartis (NVS) announced results showing consistent radiographic progression-free survival, rPFS, improvement across key subgroups with Pluvicto plus standard of care compared to SoC alone in PSMA-pos...
Experimental Novartis radiopharma drug shows promise in early study
Novartis said on Sunday that early data from its experimental actinium-based drug showed signs of anti-tumour activity against prostate cancer, including in patients previously treated with its older...
Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer
Basel, May 31, 2026 – Novartis today announced results showing consistent radiographic progression-free survival (rPFS) improvement across key subgroups with Pluvicto™ (lutetium Lu 177 vipivotide tetr...
New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength
Basel, May 26, 2026 – Novartis will present data from 15 abstracts from its kidney portfolio at this year's European Renal Association (ERA) Congress in Glasgow, June 3-6. The presentations reinforce ...
Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA
Basel, May 21, 2026 – Novartis will present data from more than 65 company or investigator sponsored abstracts at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European ...
US Supreme Court rebuffs pharma challenge to Biden-era drug price
The U.S. Supreme Court declined on Monday to hear a pharmaceutical industry challenge to a plan to curb Medicare drug prices adopted during Democratic former President Joe Biden's administration that...
Novartis announces new data from PSMAddition
Novartis (NVS) announced new data from PSMAddition demonstrating improved prostate-specific antigen, PSA, responses with Pluvicto combined with standard of care, SoC, in PSMA-positive metastatic hormo...
New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer
Basel, May 17, 2026 – Novartis today announced new data from PSMAddition demonstrating improved prostate-specific antigen (PSA) responses with Pluvicto® (lutetium (177Lu) vipivotide tetraxetan) combin...
Health Rounds: Common ADHD medicines help treat cancer-related fatigue
We also report on findings that help explain why the flu can be particularly dangerous for pregnant women and that open the door to potential future treatments.
Novartis breaks ground on radioligand therapy manufacturing site in Texas
Novartis (NVS) broke ground on its new 46,000 sq. ft radioligand therapy manufacturing site in Denton, Texas, the latest milestone in its broader $23B investment in U.S. manufacturing and research.
Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities
Basel, May 7, 2026 – Novartis, a leading global innovative medicines company, today broke ground on its new 46,000 sq. ft radioligand therapy (RLT) manufacturing site in Denton, Texas, the latest mile...
Novartis to cut 220 jobs as it closes German site
Swiss drugmaker Novartis said on Tuesday that it is set to cut around 220 jobs in Germany as part of the planned closure of a production site by the end of 2028.
Novartis announces plans to add new facility in Morrisville, North Carolina
Novartis (NVS) announced plans to add a new facility in Morrisville, North Carolina, focused on active pharmaceutical ingredient, API, manufacturing for solid dosage tablets, capsules and RNA therapeu...
UK's biggest drugmakers see surprise profit bump, even as pharma grapples with U.S. policies
Britain's largest drugmakers saw 2026 get off on a positive note, with AstraZeneca and GSK both reporting core earnings ahead of expectations on Wednesday The CEOs of a number of European pharma giant...
Novartis CEO warns of reality of Trump's drug pricing policy
Novartis' CEO warned Tuesday that the U.S. drug pricing policy under President Donald Trump poses a “very difficult situation” and the reality will soon catch up with both drugmakers and patients.
Novartis CEO warns of reality of Trump's drug pricing policy
Novartis' CEO warned Tuesday that the U.S. drug pricing policy under President Donald Trump poses a “very difficult situation” and the reality will soon catch up with both drugmakers and patients.
Novartis AG Earnings Call Transcript: Q1 2026
Priority brands and new launches drove strong Q1 growth, offsetting U.S. generic erosion and higher R&D spend. Full-year guidance is reaffirmed, with H2 expected to show stronger growth as generic impacts fade. Multiple pipeline readouts and new launches are set to support long-term growth.
Novartis AG Earnings release: Q1 2026
Novartis AG released its Q1 2026 earnings on April 28, 2026, summarizing the period's financial results.
Novartis AG Quarterly report: Q1 2026
Novartis AG has published its Q1 2026 quarterly earnings report on April 28, 2026.
Novartis AG Slides: Q1 2026
Novartis AG has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 28, 2026.
Novartis reports Q1 core EPS $1.99 vs. $2.28 last year
Reports Q1 net sales $13.11B vs. $13.23B last year. Commenting on Q1 2026 results, Vas Narasimhan, CEO of Novartis (NVS), said: “Novartis delivered a strong start to 2026 across our…
Novartis shares fall after weak Q1 hit by Entresto competition
Novartis reported first-quarter core operating profit and sales below market expectations, as generic competition for its top-selling heart drug Entresto weighed on results. Shares of the Swiss drugma...